乙型肝炎孕产妇抗病毒治疗的应用与临床路径新进展
Year: 2026
Type: article
Abstract: Mother-to-child transmission of the hepatitis B virus is a major source of chronic infection. Pregnant women with high viral loads need to have their infants immunoprophylactically on the basis of received antiviral intervention. This article reviews the application of tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) during pregnancy for the prevention of mother-to-child transmission (PMTCT) and postpartum management.TDF is supported by substantial evidence regarding its efficacy and safety for mothers and infants, while observational studies on TAF are encouraging and have been recommended in the latest guidelines. However, direct comparisons during pregnancy and long-term follow-up in infants remain insufficient. Clinically, it is essential to distinguish between long-term maternal antiviral treatment and short-term indications of interruption while implementing screening, timely medication, prompt neonatal immunoprophylaxis, and postpartum monitoring in the early stage. In resource-limited area, a strategy of initiating TDF combined with infant vaccination without hepatitis B immunoglobulin may be considered starting at 16 weeks of gestation, but timely administration and follow-up must be ensured. The long-term safety profile of TAF and the implementation effectiveness of different interruption protocol evaluations should be the focus points in the future.
Source: PubMed Central
Authors: Lin He, Li Jiawei, Huang Zhe, Calvin QPan
Language: Chinese
Topic: Hepatitis B Virus Studies
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7225321684